转自：新华财经 2025年9月24日，法国巴黎东方中心内，欧洲先锋选品会拉开帷幕。作为2025中法品牌周核心活动，这场盛会吸引了中欧数百家品牌与采购商参与。漳州片 仔癀药业股份有限公司携经典国药、化妆品、保健食品等全品类产品亮相，以"传统智慧+现代科技"的组合，成为选品会焦点。 开展首日，展台便迎来人流高峰，专业采购商络绎不绝，合作咨询不断。许多采购商对片仔癀将中医智慧与现代消费需求结合的产品理念表现出浓厚兴趣， 现场互动体验区更是排起长队。 为打破文化壁垒，片仔癀采用学术研究与体验营销双管齐下的策略，从科学结论、实验数据等维度出发，以更直观的方式帮助消费者深入了解中医药对个人 健康的益处。同时，通过在选品会现场进行产品介绍和提供试用体验，让更多人接触并认识中医药文化。越来越多的海外消费者愿意体验尝试，始于文化的 吸引力，忠于科学的健康管理。 片仔癀展台成"流量担当" 片仔癀在欧洲先锋选品会的成功，证明中医药不仅是中国的，也是全球的。从塞纳河畔的展台到欧洲消费者的日常健康管理，这片来自漳州的"绿叶"，正通 过产品创新、文化融合与渠道深耕，成长为连接东西方健康理念的桥梁，从中国品牌迈向世界品牌。（张震） 片仔癀 ...

9月25日，由紫荆文化集团主办、紫荆杂志社承办的"2025香港国际中医药大会"在香港会议展览中心盛 大启幕。本次大会以"推动中医药高质量走向世界"为主题，汇聚来自中国内地及港澳台地区、东南亚等 国家和地区的近500位专家学者、行业领袖及企业代表，包括20余位院士、国医大师、岐黄学者，以及 超过130家参展机构。漳州片仔癀药业股份有限公司（以下简称"片仔癀公司"；股票代码：600436.SH） 作为中华老字号企业及中医药文化的重要代表受邀参展，携旗下多款核心产品亮相，全面展现片仔癀公 司在传统中医药现代化与国际化进程中的积极探索与成果。 片仔癀公司展区集中展示了包括片仔癀、片仔癀牌安宫牛黄丸、复方片仔癀含片、茵胆平肝胶囊等在内 的经典中成药品，以及化妆品与保健食品系列等大健康领域产品，吸引了众多重要嘉宾、专业观众、行 业专家及媒体前来参观交流、驻足咨询。来访者纷纷对片仔癀公司传承非遗技艺与推动科技创新的成果 表示赞赏，并高度认可片仔癀公司的产品品质与文化内涵。现场洽谈气氛活跃，进一步提升了品牌在粤 港澳大湾区及国际市场的知名度。 1.依托区域优势开拓"出海"新途径 此次参展是片仔癀公司推动中医药国际化、加速品牌 ...

紫荆文化集团董事长许正中致辞表示，本次大会涵盖交流合作、学术研讨、文化传播三大核心领 域，将积极拓展产学研合作交流，深化前沿学术探讨与智慧共享，创新中医药文化国际传播，助力中医 药高质量发展。 新华社香港9月25日电（曹霁阳、郭辛）由紫荆文化集团主办、紫荆杂志社承办的2025香港国际中 医药大会25日在香港会议展览中心开幕。近500位专家学者、行业领袖及企业代表参会，超过130家机构 参展。 本次大会为期四天，以"推动中医药高质量走向世界"为主题，通过稀有中药材展览、中医药文化体 验、中医药产品展销、名医讲座等形式，展现中医药的实用价值与发展前景，吸引政、产、学、研各界 代表参与，共商中医药国际化发展的新路径与新机遇。 全国政协副主席梁振英致辞表示，香港的中医药事业正在积极主动融入国家的中医药发展大局，同 时起步走向国际。在中医药走向国际与各国传统医药交流合作这个重大课题上，我们要秉持文明互鉴的 理念，坚持互补互利精神，加强沟通，促进相互学习、相互提高，努力共同构建人类卫生健康共同体。 香港特区政府政务司司长陈国基在致辞中说，香港发展中医药具有独特的双重优势，既有祖国深厚 的中医药文化资源和底蕴，也有与国际接 ...

9月25日，由紫荆文化集团主办、紫荆杂志社承办的"2025香港国际中医药大会"在香港会议展览中心盛大启幕。本次大会以"推动中医药高质量走 向世界"为主题，汇聚来自中国内地及港澳台地区、东南亚等"一带一路"沿线国家和地区的近500位专家学者、行业领袖及企业代表，包括20余位 院士、国医大师、岐黄学者，以及超过130家参展机构。大会通过稀有中药材展览、中医药文化体验、中医药产品展销、名医讲座等多元形式，展 现中医药的实用价值与发展前景，吸引"政、产、学、研"各界代表参与，共商中医药国际化发展的新路径与新机遇。 大会开幕式现场 大会以近半小时的港式"八段锦"暨太极养生六式功法、坐式养生功法作为开场。表演者将八段锦、太极融入现代都市生活场景，为繁忙的"上班 族"提供了简易的健身方式，现场观众反应热烈，并纷纷跟学模仿，展现了中医文化在日常健康管理中的实用性。会场同步开设诸多名企展区，展 出多种珍贵中药材，配以图文解说，帮助参观者深入了解药材特性与临床应用，为大家提供了广阔的交流平台。 全国政协副主席梁振英，香港特别行政区政府政务司司长陈国基，中央政府驻港联络办副主任尹宗华，外交部驻港特派员公署特派员崔建春，吉 林省人民 ...

9月25日，由紫荆文化集团主办、紫荆杂志社承办的"2025香港国际中医药大会"在香港会议展览中心盛大启幕。本次大会以"推动中医药高质量走向世 界"为主题，汇聚来自中国内地及港澳台地区、东南亚等"一带一路"沿线国家和地区的近500位专家学者、行业领袖及企业代表，包括20余位院士、国医大 师、岐黄学者，以及超过130家参展机构。大会通过稀有中药材展览、中医药文化体验、中医药产品展销、名医讲座等多元形式，展现中医药的实用价值 与发展前景，吸引"政、产、学、研"各界代表参与，共商中医药国际化发展的新路径与新机遇。 大会以近半小时的港式"八段锦"暨太极养生六式功法、坐式养生功法作为开场。表演者将八段锦、太极融入现代都市生活场景，为繁忙的"上班族"提供了 简易的健身方式，现场观众反应热烈，并纷纷跟学模仿，展现了中医文化在日常健康管理中的实用性。会场同步开设诸多名企展区，展出多种珍贵中药 材，配以图文解说，帮助参观者深入了解药材特性与临床应用，为大家提供了广阔的交流平台。 【导读】2025香港国际中医药大会在港启幕，以全球智慧共谋中医药高质量走向世 中国基金报记者 郭玟君 大会 以近半小时的港式"八段锦"暨太极养生六式功法 ...

【导读】 2025香港国际中医药大会在港启幕，以全球智慧共谋中医药高质量走向世 中国基金报记者 郭玟君 9月25日，由紫荆文化集团主办、紫荆杂志社承办的"2025香港国际中医药大会"在香港会议 展览中心盛大启幕。本次大会以"推动中医药高质量走向世界"为主题，汇聚来自中国内地及 港澳台地区、东南亚等"一带一路"沿线国家和地区的近500位专家学者、行业领袖及企业代 表，包括20余位院士、国医大师、岐黄学者，以及超过130家参展机构。大会通过稀有中药 材展览、中医药文化体验、中医药产品展销、名医讲座等多元形式，展现中医药的实用价值 与发展前景，吸引"政、产、学、研"各界代表参与，共商中医药国际化发展的新路径与新机 遇。 大会开幕式现场 大会以近半小时的港式"八段锦"暨太极养生六式功法、坐式养生功法作为开场。表演者将八 段锦、太极融入现代都市生活场景，为繁忙的"上班族"提供了简易的健身方式，现场观众反 应热烈，并纷纷跟学模仿，展现了中医文化在日常健康管理中的实用性。会场同步开设诸多 名企展区，展出多种珍贵中药材，配以图文解说，帮助参观者深入了解药材特性与临床应 用，为大家提供了广阔的交流平台。 全国政协副主席梁振英， ...

Core Viewpoint - Huachuang Yuxin (600155.SH) announced a lawsuit against Guizhou Bailing (002424.SZ) major shareholder Jiang Wei and his associates, involving a total amount of 1.761 billion yuan, which has attracted significant attention in the capital market [1] Company Overview - Guizhou Bailing, originally Anshun Pharmaceutical Factory, transformed from a loss-making entity to a leading national herbal medicine company under Jiang Wei's leadership, achieving a production value increase from 2 million to 10 million yuan in the same year [1] - The company went public in June 2010 and is known as the "first stock of herbal medicine," holding 167 approved drug licenses and 11% of the national herbal medicine licenses by 2018 [1] Financial Performance - Guizhou Bailing's stock price has declined significantly since 2017, with its market value shrinking to approximately 12 billion yuan by the end of 2018 [1] - From 2019 to 2021, Guizhou Bailing experienced a continuous decline in net profit, with decreases of 48.27%, 46.11%, and 18.49% respectively [2] - R&D investment dropped by 30% during the same period, contributing to a loss of market share and a more than 75% decline in net profit compared to its peak in 2018 [2] Debt and Legal Issues - The lawsuit stems from a 2019 financial support plan where Huachuang Securities provided 1.4 billion yuan to Jiang Wei, acquiring 11.54% equity in Guizhou Bailing [2] - Jiang Wei has reportedly paid approximately 2.1 billion yuan in interest and a total of 4.2 billion yuan in principal and interest by the second quarter of 2025 [3] - The lawsuit seeks repayment of the principal amount of 1.4 billion yuan and related costs due to insufficient stock value to recover the funds [3] Strategic Developments - Guizhou Bailing is expanding into international markets, establishing a company in Macau for overseas trade and registering products in various countries [4] - The company projects a revenue of 4 billion yuan and a net profit of 120 million yuan by 2025, aiming to enhance profitability through product integration [4] Market Performance - Since hitting a low in June 2024, Guizhou Bailing's stock has rebounded strongly, with an increase of nearly 90% from its previous low [5]

Core Viewpoint - Yiling Pharmaceutical is accelerating its international expansion, particularly in the anti-aging product sector, as evidenced by the positive reception from Brazilian media executives who are eager to introduce these products to the Brazilian market [1] Group 1: Company Strategy and Innovation - Yiling Pharmaceutical adheres to the principle of "inheritance and innovation" and employs a five-in-one innovative operational model that integrates theory, clinical practice, research, industry, and education, creating a virtuous cycle for sustainable development [3] - The company has established over 60 medicinal herb planting bases across more than 20 provinces in China to ensure high-quality raw materials, adhering to strict planting standards and management systems [5] Group 2: Quality Control and Research - Yiling Pharmaceutical's production facilities have passed international certifications, including those from the US and EU, and have implemented a comprehensive quality management system to ensure the safety and efficacy of its products [5] - The research team collaborates with top international medical research institutions, conducting high-standard evidence-based medical studies and publishing over 300 SCI papers, which validate the efficacy and safety of traditional Chinese medicine [5] Group 3: Brand Development and Market Penetration - The company has developed a systematic theory of "Luo Disease," which has garnered significant attention and multiple national awards, enhancing the brand's credibility and recognition in the international market [6] - Yiling Pharmaceutical has launched 17 patented traditional Chinese medicine products across various clinical fields, including cardiovascular, respiratory, endocrine, oncology, and aging, with a presence in over 50 countries and regions worldwide [7]

Core Viewpoint - The 2025 Service Trade Fair in Beijing showcased Beijing Tongrentang Group's innovative approach to traditional Chinese medicine, emphasizing its commitment to cultural heritage, technological integration, and global expansion [1][19]. Classic Inheritance - Beijing Tongrentang highlighted its dedication to traditional practices through the "Classic Inheritance" section, showcasing its renowned products like An Gong Niu Huang Wan and various herbal medicines, emphasizing quality and historical significance [2][3]. - The company has revived two previously dormant products, Jie Yu Wan and An Shen Wan, after extensive research to meet public health needs [2]. Technological Empowerment - The establishment of a key laboratory for innovative research in traditional medicine demonstrates the company's commitment to integrating technology with traditional practices, aiming to enhance disease prevention and treatment [4][5]. - The "Smart Health Service Zone" introduced interactive experiences for consumers, allowing them to engage with traditional medicine in a modern context [4][5]. National Trend and Global Expansion - The launch of the "Yin Yang Su" toothpaste series reflects the company's strategy to merge traditional Chinese medicine with contemporary consumer trends, focusing on natural ingredients and health benefits [9][10]. - International collaborations were highlighted, including the licensing of An Gong Niu Huang Wan in Cambodia and a memorandum of understanding with Uruguay for traditional medicine cooperation, showcasing the global outreach of Chinese medicine [13][14]. Academic Leadership - The third Traditional Chinese Medicine Conference held during the fair served as a platform for academic exchange, featuring discussions on innovative research and traditional practices, reinforcing the company's role in advancing the industry [15][16]. Public Welfare Practices - The company implemented a dual online and offline health service model during the fair, promoting easy access to health products and personalized health management solutions [18][19]. - The "Weight Management Zone" provided tailored weight loss plans based on traditional Chinese medicine principles, demonstrating the company's commitment to public health [19].

Core Viewpoint - The 2025 China International Service Trade Fair (CIFTIS) showcased the integration of traditional Chinese medicine (TCM) with advanced technologies such as artificial intelligence, big data, and the Internet of Things, highlighting a transformative approach to health services that encompasses prevention, treatment, and rehabilitation [1][5]. Group 1: Technological Innovations in TCM - The fair featured numerous TCM institutions, with a focus on digital transformation, including AI-assisted diagnostic tools and smart manufacturing for precise extraction of herbal formulas [1][2]. - The China Academy of Chinese Medical Sciences presented AI robots capable of performing the four diagnostic methods of TCM, enhancing the interaction between patients and technology [2]. - The SY-3 digital TCM treatment robot, developed by Zhongke Shangyi, utilizes AI for rapid meridian path planning and precise treatment, showcasing the modernization of TCM practices [3]. Group 2: Internationalization of TCM - The digital innovations are propelling TCM products and services to international markets, gaining broader recognition globally [5]. - Renowned companies like Tongrentang are actively registering products like the An Gong Niu Huang Wan in countries such as Cambodia and Vietnam, indicating a strategic push for international market entry [6]. - The release of the Arabic version of the "Chinese Medicinal Material Identification Atlas" marks a significant milestone in TCM's outreach to the Arab world, enhancing collaboration in the field [6][7]. Group 3: Standardization and Cultural Exchange - The fair introduced the "Acupuncture and Massage Meridian Points Atlas" for African populations, establishing a new paradigm for standardizing TCM practices while adapting to local characteristics [7]. - Various international cooperation agreements were signed, including strategic partnerships in TCM between Chinese and French institutions, promoting cross-border collaboration [6][7]. - The event also featured activities that promote TCM culture, such as the "24 Solar Terms Health Check-in," which aims to engage a global audience in TCM practices [7].